GlassScriptPhysician profile
Clarence R Alexander
NPI 1154394153
$13,660.52
in general payments reported to CMS, 2019-2025
58 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,848 · 2020: $1,847 · 2021: $1,727 · 2022: $1,972 · 2023: $1,817 · 2024: $2,296 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,265.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,007.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,527.87 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $1,304.18 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $982.41 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $954.47 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $781.77 | 2019-2025 | |
| Lilly USA, LLC | $628.38 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $451.52 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Amgen INC. | $445.41 | 2019-2025 | Evenity, Prolia, Krystexxa |
| Novartis Pharmaceuticals Corporation | $367.38 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $357.49 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $355.37 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $230.57 | 2019-2022 | |
| Abbott Laboratories | $201.00 | 2019-2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $199.59 | 2023-2025 | Gemtesa |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarence Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.